Key Facts

Invested since 2012
Based in Hamburg

About the company

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.

Do you want to

know more about this company?

Zum Artikel

Dr. Lena-Sophie Schütter Investment Manager

Dr. Lena-Sophie SchütterInvestment Manager

GQ Bio Therapeutics in the news

Zum Artikel

News

28. February 2025

Successful exit for HTGF: Pacira BioSciences Acquires GQ Bio

Series A Investment GeneQuine Zum Artikel

News

26. January 2021

GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases

Zum Artikel

Press

12. November 2012

GeneQuine Biotherapeutics Closes Seed Financing with High-Tech Gründerfonds and Innovationsstarter Fonds Hamburg

More startups from Life Sciences